A Clinical Trial to Search the Efficacy of Homoeopathic Treatment in Allergic Rhinitis and/or Bronchial Asthma

An Evidence-based Single-blind Randomized Controlled Trial Searching for the Efficacy of Homoeopathic Medicines in Reducing Serum Levels of Cytokines (IL â?? 10, 13) and Immunoglobulin E in Allergic Rhinitis and/or Induced Bronchial Asthma - SBRCTHMILARBA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/02/002419

Enrollment

100

Registered

2012-02-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Age between 5 and 65 years, both sexes, atopic to allergens with positive skin prick test results and eosinophilia and more than 1 year history of allergic rhinitis or induced bronchial asthma

Interventions

Intervention1: Homeopathic medicines: Intervention - 5 ml dose of Homeopathic medicine in 6/30/200/1M/10M/50M or 0/1 - 0/40 potency OD/BDS/TDS/QDS or as appropriate for 1 year. Control Intervention1:

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age between 5 and 65 years 2. Both sexes 3. Atopic: reactive to allergens with positive skin prick test (SPT) results and/or eosinophilia 4. More than 1 year history of allergic rhinitis and/or induced bronchial asthma

Exclusion criteria

Exclusion criteria: 1. Nasal abnormalities causing obstruction, e.g. nasal polyp(s), deviated septum etc. 2. Previous homoeopathic immunotherapy for allergic rhinitis 3. Allergen avoidance in past 6 weeks 4. Away from usual environment for more than 1 week during trial 5. Severe asthma cases as detected clinically 6. Respiratory infection 7. Severe concomitant disease 8. Pregnancy, breast feeding, or likelihood of pregnancy 9. Oral or parenteral steroids and/or decongestant in past 6 months 10. Conventional desensitization in past 3 months

Design outcomes

Primary

Measure	Time frame
1. Serum Interleukin 10 and 13 level 2. Serum Immunoglobulin E level 3. Absolute Eosinophil countTimepoint: Serum interleukin 10, 13 and immunoglobulin E after 1 year of treatment and absolute eosinophil count every 4 months up to 1 year	—

Secondary

Measure	Time frame
1. Clinical improvement in symptom scores 2. Halt of the disease progress and complications and prevention of relapse 3. Incidence of adverse events if anyTimepoint: 1 year of treatment	—

Countries

India

Contacts

Public ContactShubhamoy Ghosh

Mahesh Bhattacharyya Homoeopathic Medical College and Hospital Government of West Bengal

shubhamoy67@gmail.com09804151933

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026